Fremont, California-based Verseon International Corporation has acquired Iowa City, Iowa-based Edammo, Inc. Terms of the deal were not disclosed.
Verseon International Corporation is a clinical-stage pharmaceutical company. It is developing several drug discovery programs in cardiometabolic diseases and cancer featuring drug candidates that represent novel chemical matter designed using molecular physics and artificial intelligence. Verseon’s pipeline includes seven drug programs in the areas of anticoagulation, diabetic retinopathy, hereditary angioedema, oncology and metabolic disorders.
Edammo provides businesses and individuals with real-time predictive analytics. Edammo developed the Extreme AutoML platform.
According to the LevinPro HC database, this transaction was the 285th eHealth deal of 2022. This compares with 289 eHealth deals recorded between January 1, 2021, and October 20, 2021.
